Drugs & Aging

, Volume 19, Issue 8, pp 571–581

Acute Myeloid Leukaemia

Optimising Treatment in Elderly Patients
Therapy In Practice

Abstract

Acute myeloid leukaemia (AML) is a disease of the elderly (median age at presentation 64 years). The outcome in older patients with AML is much worse than that for similarly treated younger patients. Older patients have a high incidence of recognised poor prognostic features (poor performance status, unfavourable cytogenetics, CD34 positive phenotype, raised serum lactate dehydrogenase levels and increased incidence of multidrug resistance protein expression). In addition, treatment is less well tolerated as there is an increased incidence of comorbidity in the elderly.

The outlook for most patients is poor (4% survival at 5 years). However, it is possible to select a group of patients who are fit, with no pre-existing problems and good performance status who will respond well to intensive chemotherapy, and these patients should be treated aggressively. Less intensive treatment is probably more suitable for patients not fitting these criteria. Patients and their relatives should be counselled appropriately as to the prognosis of AML, the choices of treatment available and that intensive regimens are not an appropriate choice for many patients.

References

  1. 1.
    Northern Region Haematology Group. Annual Report. England: Northern Region Haematology Group, 2000Google Scholar
  2. 2.
    Johnson PRE, Hunt LP, Liu Yin JA. Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival. Br J Haematol 1993; 85: 300–6PubMedCrossRefGoogle Scholar
  3. 3.
    Burge PS, Richards JDM, Thompson DS, et al. Quality and quantity of survival in acute myeloid leukaemia. Lancet 1975; 2: 621–4PubMedCrossRefGoogle Scholar
  4. 4.
    Letendre L, Noel P, Litzow MR, et al. Treatment of acute myelogenous leukemia in the older patient with attenuated highdose Ara-C. Am J Clin Oncol 1998; 21: 142–4PubMedCrossRefGoogle Scholar
  5. 5.
    Keating MJ, Smith TL, Kantarjian H, et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 1988; 2(7): 403–12PubMedGoogle Scholar
  6. 6.
    Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood 1998; 92(7): 2322–33PubMedGoogle Scholar
  7. 7.
    Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 2001; 58(18): 4173–9Google Scholar
  8. 8.
    Buchner T, Hiddemann W, Wormann B, et al. Late events in AML. Data from long-term observation of patients in two trials starting in 1981 and 1985 [abstract]. Blood 1997; 90 (10): 504aGoogle Scholar
  9. 9.
    Taylor P, Bown N, Cuthbert G, et al. A population based study of de-novo AML to assess karyotype incidence pattern and its impact on survival by age cohorts [abstract]. Ann Haematol 2001; 80: S19Google Scholar
  10. 10.
    Bow EJ, Sutherland JA, Kilpatrick MG, et al. Therapy of untreated acute myeloid leukemia in the elderly: remission induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J Clin Oncol 1996; 14(4): 1345–52PubMedGoogle Scholar
  11. 11.
    Proctor SJ, Taylor PRA. Age cohort subgroups in adult acute myeloid leukaemia studies: the population perspective. Leukemia 2001; 15(1): 188–9PubMedCrossRefGoogle Scholar
  12. 12.
    Schoch C, Haase D, Haferlach T, et al. Fifty-one patients with acute myeloid leukemia and translocation t(8; 21)(q22; q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia 1996; 10(8): 1288–95PubMedGoogle Scholar
  13. 13.
    Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89(9): 3323–9PubMedGoogle Scholar
  14. 14.
    Ferrara F, Mirto S. Serum LDH value as a predictor of clinical outcome in actue myelogenous leukaemia of the elderly. Br J Haematol 2001; 92(3): 627–31CrossRefGoogle Scholar
  15. 15.
    Behringer B, Kunzmann R, Schmoor C, et al. Serum lactate dehydrogenase (LDH) as anindependent prognostic factor for overall survival in patients with acute myeloid leukemia (AML) aged > 55 years [abstract]. Blood 2000; 96(11): 123aGoogle Scholar
  16. 16.
    Taylor PRA, Reid MM, Stark AN, et al. De-novo acute myeloid leukaemia in patients over 55 years old: a population based study of incidence, treatment and outcome. Leukemia 1995; 9(2):231–7PubMedGoogle Scholar
  17. 17.
    Rees JKH, Gray RG, Swirsky D, et al. Principal results of the Medical Research Council’s 8th acute myeloid leukaemia trial. Lancet 1986; II: 1236–41CrossRefGoogle Scholar
  18. 18.
    Preisler H, Davis RB, Kirshner J, et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukaemia: a Cancer and Leukemia Group B study. Blood 1987; 69(5): 1441–9PubMedGoogle Scholar
  19. 19.
    Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood 1991; 78(10): 2520–6PubMedGoogle Scholar
  20. 20.
    Liu Yin JA, Johnson PRE, Davies JM, et al. Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia. Br J Haematol 1991; 79: 415–20PubMedCrossRefGoogle Scholar
  21. 21.
    Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331(14): 896–903PubMedCrossRefGoogle Scholar
  22. 22.
    Lowenberg B, Suciu S, Archimbaud E, et al. Mitroxantrone vs daunorubicin in induction-consolidation chemotherapy: the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly. J Clin Oncol 1998; 16(3): 872–81PubMedGoogle Scholar
  23. 23.
    Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982; 60(2): 454–62PubMedGoogle Scholar
  24. 24.
    Kahn SB, Begg CB, Mazza JJ, et al. Full dose vs attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1984; 2(8): 865–70PubMedGoogle Scholar
  25. 25.
    Baudard M, Marie JP, Cadiou M, et al. Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol 1994; 86: 82–91PubMedCrossRefGoogle Scholar
  26. 26.
    Pulsoni A, Pagano L, Tosti ME, et al. Retrospective survival analysis of elderly patients with acute myeloid leukemia (aml) treated with aggressive or non aggressive therapy [abstract]. Blood 2000; 96(11): 2166aGoogle Scholar
  27. 27.
    Gandhi V, Plunkett W. Modulation of arabinosyl nucleoside metabolism by arabinosyl nucleotides in human leukaemia cells. Cancer Res 1988; 48: 329–34PubMedGoogle Scholar
  28. 28.
    Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarbine induction therapy of newly diagnosed acute myelogenous leukaemia or myelodysplastic syndromes: comparison with fludarabine plus cytarbine without granulocyte colony-stimulating factor. J Clin Oncol 1994; 12(4): 671–8PubMedGoogle Scholar
  29. 29.
    Jackson G, Taylor P, Smith GM, et al. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol 2001; 112: 127–37PubMedCrossRefGoogle Scholar
  30. 30.
    Arlin Z, Case Jr DC, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphoctytic leukemia (ANLL). Leukemia 1990; 4(3): 177–83PubMedGoogle Scholar
  31. 31.
    Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukaemia: a report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103(4): 620–5PubMedGoogle Scholar
  32. 32.
    Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72(2): 567–72PubMedGoogle Scholar
  33. 33.
    Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94(4): 1192–200PubMedGoogle Scholar
  34. 34.
    Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood 1981; 58: 1203–11PubMedGoogle Scholar
  35. 35.
    McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumour effects. Blood 2001; 97(11): 3390–400PubMedCrossRefGoogle Scholar
  36. 36.
    Groot C-D, Lowenberg B, Vellenga E, et al. Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukaemia. Br J Haematol 1998; 100(4): 629–36CrossRefGoogle Scholar
  37. 37.
    Heil G, Hoelzer D, Sanz MA, et al. A randomized, doubleblind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997; 90(12): 4710–8PubMedGoogle Scholar
  38. 38.
    Ruutu T, Almqvist A, Hallman H, et al. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Leukemia 1994; 8(1): 11–5PubMedGoogle Scholar
  39. 39.
    Jackson GH, Taylor PRA, Iqbal A, et al. The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy. Leukemia 1997; 11: 1193–6PubMedCrossRefGoogle Scholar
  40. 40.
    Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990; 8(2): 272–9PubMedGoogle Scholar
  41. 41.
    Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtruzumab ozogamicin in patients with CD-33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19(13): 3244–54PubMedGoogle Scholar
  42. 42.
    Lee EJ, George SL, Caligiuri M, et al. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of Cancer and Leukemia Group B study 9420. J Clin Oncol 1999; 17(9): 2831–9PubMedGoogle Scholar
  43. 43.
    Wattel E, Solary E, Hecquet B, et al. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing p glycoprotein: results of a randomized study. Br J Haematol 1998; 102: 1015–24PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Department of HaematologyRoyal Victoria InfirmaryNewcastle Upon TyneUK

Personalised recommendations